EndoCeutics, Inc. · Quebec City, QC Canada
| 2989, De La Promenade | Phone: +1-418-652-0197 |
| Quebec City, QC | |
| G1W 2J5 | |
| Canada | 
Map This Company |
EndoCeutics, Inc. Rankings
Company Description
Ending breast cancer is top priority at EndoCeutics. The trial-phase biopharmaceutical company develops hormone therapies for treating and preventing breast cancer and endocrine-related disorders affecting postmenopausal women, as well as aging men. The company specializes in phase III clinical trials and commercialization of pharmaceuticals. Its leading product candidate, acolbifene, is a selective estrogen receptor modulator (SERM) that inhibits the stimulatory effect that estrogen (a female sex hormone) has on the growth of breast and uterine cancer. Other products include DHEA for use in treatment of postmenopausal women suffering from vaginal atrophy.
EndoCeutics, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | PrivateHeadquarters |
|---|---|
| Fiscal Year-End | December |
| Employees | 1 |
Executives
2 executives listed for EndoCeutics, Inc.'s Quebec City, QC location.
| President, CEO, Chief Scientific Officer, and Director | Fernand Labrie | |
|---|---|---|
| CFO | Claude Doré |